ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company, announced on July 3, 2025, the issuance of inducement grants to a new non-executive employee, effective from July 1, 2025. As part of the compensation package, the employee received 9,000 non-qualified stock options and 1,600 restricted stock units, approved by ORIC's Compensation Committee under Nasdaq Rule 5635(c)(4). The stock options have an exercise price set at the closing price of ORIC's common stock on the grant date. Vesting terms for the stock options include 25% vesting after one year and the remainder vesting monthly over the following three years, while the restricted stock units vest in equal parts over three years. These grants were made under the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。